Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 129Carcinoma, Renal Cell 36Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 27Cholangiocarcinoma 23Endometrial Neoplasms 19Liver Neoplasms 16Melanoma 15Thyroid Neoplasms 13Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 12Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma 4Thyroid Cancer, Papillary 3Solid Tumors 3

Interventions

Paclitaxel 2lenvatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × lenvatinib × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡